Insider Trading Alert - AMRI, AMRK And WIFI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 13, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $377.89 to $223,379,993.30.

Highlighted Stocks Traded by Insiders:

Albany Molecular Research (AMRI) - FREE Research Report

D Ambra Constance M, who is 10% Owner at Albany Molecular Research, sold 20,000 shares at $19.11 on May 13, 2015. Following this transaction, the 10% Owner owned 2.4 million shares meaning that the stake was reduced by 0.81% with the 20,000-share transaction.

D Ambra Thomas E Phd, who is Chairman, Board of Directors at Albany Molecular Research, sold 20,000 shares at $19.11 on May 13, 2015. Following this transaction, the Chairman, Board of Directors owned 2.6 million shares meaning that the stake was reduced by 0.77% with the 20,000-share transaction.

The shares most recently traded at $19.38, up $0.27, or 1.39% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

• 4-Week # shares bought: 10,000

• 4-Week # shares sold: 40,000

• 12-Week # shares bought: 30,000

• 12-Week # shares sold: 84,662

• 24-Week # shares bought: 30,000

• 24-Week # shares sold: 206,285

The average volume for Albany Molecular Research has been 457,800 shares per day over the past 30 days. Albany Molecular Research has a market cap of $633.9 million and is part of the health care sector and drugs industry. Shares are up 17.57% year-to-date as of the close of trading on Wednesday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. Currently, there are 2 analysts who rate Albany Molecular Research a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.